(R)-2-<(benzyloxy)carbonylamino>-3-(thiophen-2-yl)propanoic acid | 117467-72-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-2-<(benzyloxy)carbonylamino>-3-(thiophen-2-yl)propanoic acid
• 英文别名: (R)-(N-benzyloxycarbonyl)-3-(2-thienyl)alanine；(2R)-2-(phenylmethoxycarbonylamino)-3-thiophen-2-ylpropanoic acid
• CAS: 117467-72-8
• 化学式: C₁₅H₁₅NO₄S
• 分子量: 305.354
• InChiKey: CKJLJMFZZAWDKK-CYBMUJFWSA-N

物化性质

• 沸点：
  518.8±50.0 °C(Predicted)
• 密度：
  1.331±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (R)-2-<(benzyloxy)carbonylamino>-3-(thiophen-2-yl)propanoic acid 在 N-甲基吗啉 、 lithium aluminium tetrahydride 、 [VCl3(thf)3] 、 铜 、 锌 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 7.25h， 生成 ((1R,2S,3S,4R)-4-Benzyloxycarbonylamino-2,3-dihydroxy-5-thiophen-2-yl-1-thiophen-2-ylmethyl-pentyl)-carbamic acid benzyl ester
  参考文献：
  名称：

  Preparation and Structure−Activity Relationship of Novel P1/P1‘-Substituted Cyclic Urea-Based Human Immunodeficiency Virus Type-1 Protease Inhibitors

  摘要：

  A series of novel P1/P1'-substituted cyclic urea-based HIV-1 protease inhibitors was prepared. Three different synthetic schemes were used to assemble these compounds. The first approach uses amino acid-based starting materials and was originally used to prepare DMP 323. The other two approaches use L-tartaric acid or L-mannitol as the starting material. The required four contiguous R,S,S,R centers of the cyclic urea scaffold are introduced using substrate control methodology. Each approach has specific advantages based on the desired P1/P1' substituent. Designing analogs based on the enzyme's natural substrates provided compounds with reduced activity. Attempts at exploiting hydrogen bond sites in the S1/S1' pocket, suggested by molecular modeling studies, were not fruitful. Several analogs had better binding affinity compared to our initial leads. Modulating the compound's physical properties led to a 10-fold improvement in translation resulting in better overall antiviral activity.

  DOI：

  10.1021/jm960083n
• 作为产物：
  描述：

  3-(2-噻吩基)-DL-丙氨酸 在 N-甲基吗啉 、 甲醇 、 4 A molecular sieve 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 25.0h， 生成 (R)-2-<(benzyloxy)carbonylamino>-3-(thiophen-2-yl)propanoic acid
  参考文献：
  名称：

  通过金鸡纳生物碱催化的氨基甲酸酯保护的α-氨基酸N-羧基酸酐的动力学拆分，α-氨基酸的不对称合成。

  摘要：

  DOI：

  10.1021/ja011936q

文献信息

• Synthesis of Enantiomerically Pure<scp>D</scp>- and<scp>L</scp>-(Heteroaryl)alanines by asymmetric hydrogenation of (<i>Z</i>)-α-amino-αβ-didehydro esters
  作者：Thierry Masquelin、Emil Broger、Klaus Müller、Rudolf Schmid、Daniel Obrecht

  DOI：10.1002/hlca.19940770518

  日期：1994.8.10

  Isomerically pure (Z)-α-amino-α,β-didehydro esters were required to obtain the highest enantiomeric excesses (ee's) in the asymmetric hydrogenation, and the tert-butyl-ester strategy was beneficial in terms of both getting pure (Z)-α-amino-α,β-didehydro esters and obtaining high ee's in the hydrogenation. Finally, in contrast to the methyl-ester series, deprotection of the tert-butyl esters 4a–d, g was easily

  由二磷杂铑催化剂催化的各种甲基和叔丁基（Z）-2-（酰基氨基）-3-（杂芳基）丙烯酸酯的均相不对称氢化反应（见1a-f和2a-d，f，g，分别）对合成对映体纯的3-呋喃基，3-噻吩基和3-吡咯基丙氨酸进行了研究（参见3a–f和4a–d，g；方案1）。使用磷酸甘氨酸酯法（方案1）以高收率制备了前体（Z）-α-氨基-α，β-二氢化酯1a-f和2a-d，f，g。异构纯（Z）-α-氨基-α，β-二氢化酯需要获得不对称氢化中最高的对映体过量（ee's），而叔丁基酯策略从获得纯净的（Z）-α-氨基-α，β-二氢氢化酯，在氢化反应中获得较高的ee值。最后，与甲基酯系列相反，叔丁基酯4a-d，g的脱保护很容易使用CF 3 CO 2 H进行，没有任何消旋作用。
• NOVEL OPTICALLY ACTIVE COMPOUNDS, METHOD FOR KINETIC OPTICAL RESOLUTION OF CARBOXYLIC ACID DERIVATIVES AND CATALYSTS THEREFOR
  申请人：DAISO CO., LTD.

  公开号：EP1477488B1

  公开（公告）日：2009-08-26
• Asymmetric Synthesis of α-Amino Acids via Cinchona Alkaloid-Catalyzed Kinetic Resolution of Urethane-Protected α-Amino Acid <i>N</i>-Carboxyanhydrides
  作者：Jianfeng Hang、Shi-Kai Tian、Liang Tang、Li Deng

  DOI：10.1021/ja011936q

  日期：2001.12.19
• Preparation and Structure−Activity Relationship of Novel P1/P1‘-Substituted Cyclic Urea-Based Human Immunodeficiency Virus Type-1 Protease Inhibitors
  作者：David A. Nugiel、Kim Jacobs、Tabitha Worley、Mona Patel、Robert F. Kaltenbach、Dayton T. Meyer、Prabhakar K. Jadhav、George V. De Lucca、Thomas E. Smyser、Ronald M. Klabe、Lee T. Bacheler、Marlene M. Rayner、Steven P. Seitz

  DOI：10.1021/jm960083n

  日期：1996.1.1

  A series of novel P1/P1'-substituted cyclic urea-based HIV-1 protease inhibitors was prepared. Three different synthetic schemes were used to assemble these compounds. The first approach uses amino acid-based starting materials and was originally used to prepare DMP 323. The other two approaches use L-tartaric acid or L-mannitol as the starting material. The required four contiguous R,S,S,R centers of the cyclic urea scaffold are introduced using substrate control methodology. Each approach has specific advantages based on the desired P1/P1' substituent. Designing analogs based on the enzyme's natural substrates provided compounds with reduced activity. Attempts at exploiting hydrogen bond sites in the S1/S1' pocket, suggested by molecular modeling studies, were not fruitful. Several analogs had better binding affinity compared to our initial leads. Modulating the compound's physical properties led to a 10-fold improvement in translation resulting in better overall antiviral activity.